Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immunex Enbrel

Executive Summary

More than 70,000 existing etanercept patients have registered for Enbrel's Enrollment Program, the company says. A waiting list, established for patients registering after Dec. 31, consists primarily of prospective Enbrel users. Wyeth/Immunex started the program to help ensure uninterrupted therapy for Enbrel patients during a projected temporary shortage (1"The Pink Sheet" Nov. 27, 2000, p. 3). Wyeth-Ayerst expects to break ground mid-2001 on the construction of a 1 mil. square foot Ireland plant that will likely take four to five years to complete. Enbrel's North American supply is also expected to double following the completion of a 250,000-square foot West Greenwich, R.I. facility in 2002

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel